DexCom: G7 CGM System to be covered for Medicare beneficiaries

Dexcom announced earlier that its next-generation Dexcom G7 CGM System will be covered for Medicare beneficiaries. Having met the category requirements for therapeutic CGM systems set forth by the U.S. Centers for Medicare & Medicaid Services, Dexcom G7 will be accessible to all Medicare patients with diabetes who meet the eligibility criteria when the system launches this Friday, Feb. 17. "When we set out to design G7, our goal was simple: to make the most accurate, easy-to-use CGM available for as many people with diabetes as possible," said Kevin Sayer, chairman, president and CEO of Dexcom. "The approval of Medicare coverage for G7 helps us deliver on that promise. Now Medicare patients with Type 1 and Type 2 diabetes will have access to the newest CGM technology that offers the most reliable, simple way to help people manage their diabetes more confidently."